SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
Search
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
tomato_and_carrot_soup.pdf
TOviTO_Wheel_Interactive_PDF_05122018_2.pdf
tovito_info_0.pdf
Glutamate receptor modulator
Glutamate receptor modulator
Glutamate receptor modulator
Boehringer Ingelheim Office Hours Video 2023
Boehringer Ingelheim’s Office Hours program provides mentoring and access to expertise to help early-stage companies advance their science.
Green Chemistry
Green Chemistry is critical for us as it balance the long-term sustainability of business, society, and the environment.
Ethical Business Practices
Suppliers shall conduct their business in an ethical manner and act with integrity.
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
COVID-19
As a research-driven company, we are part of the collective effort in fighting COVID-19. Learn more about our ongoing engagement in the fight against COVID-19
EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
About Us
About us